Streetbeat News

Analyst Ratings

AVB

Deutsche Bank analyst Derek Johnston maintains a Buy rating on AvalonBay Communities (NYSE:AVB) and raises the price target from $206 to $249.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:49 pm

SPWH

Roth MKM analyst Matt Koranda maintains a Buy rating on Sportsman's Warehouse (NASDAQ:SPWH) but lowers the price target from $5 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:47 pm

MNR

Raymond James analyst John Freeman maintains a Strong Buy rating on Mach Natural Resources (NYSE:MNR) but lowers the price target from $27 to $22.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:46 pm

INSP

Leerink Partners has maintained a Market Perform rating on Inspire Medical Systems (NYSE:INSP) while raising the price target from $167 to $197.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:44 pm

VRDN

HC Wainwright & Co. has reiterated its Buy rating for Viridian Therapeutics, maintaining a price target of $27. Analyst Douglas Tsao continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:43 pm

CORZ

Bernstein analyst Gautam Chhugani has reiterated an Outperform rating for Core Scientific (NASDAQ:CORZ) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:41 pm

SHOP

JMP Securities analyst Andrew Boone has reiterated a Market Outperform rating for Shopify (NYSE:SHOP) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:37 pm

CGNT

Needham analyst Mike Cikos has reiterated a Hold rating on Cognyte Software (NASDAQ:CGNT).

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:29 pm

JNJ

PTGX

TAK

Truist Securities initiated coverage on Protagonist Therapeutics (PTGX) with a Buy rating and a $60 price target, highlighting its promising investigational candidates rusfertide and JNJ-2113. These assets target a market exceeding $10 billion, with significant potential in blood cancer and psoriasis treatments. Partnerships with Takeda and Johnson & Johnson bolster PTGX's prospects.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 5:17 pm

OXY

Occidental Petroleum (NYSE:OXY) is experiencing significant bearish sentiment from large investors, as revealed by Benzinga's options scanner. The options activity shows a majority of bearish positions, with a predicted price range of $30 to $60. The stock is currently trading at $51.05, down 1.74%, and analysts have mixed ratings with a consensus target price of $71.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 5:15 pm